American Water Works Company Inc vs Summit Therapeutics Inc — how do they compare? American Water Works Company Inc trades at $131.69 (market cap $25.69B), while Summit Therapeutics Inc trades at $15.9 (market cap $12.01B). The key difference: American Water Works Company Inc is far larger — about 2.1× Summit Therapeutics Inc's market cap, and American Water Works Company Inc pays a 2.72% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AWK | SMMT | |
|---|---|---|
Market Cap | $25.69B | $12.01B |
Sector | Utilities | Health |
52-Week High | $147.00 | $29.32 |
52-Week Low | $121.13 | $13.05 |
Enterprise Value | $41.25B | $11.43B |
Dividend Yield | 2.72% | — |
Signals from Pluang's Aura AI — not financial advice
American Water Works (AWK) trades at $131.53, up 0.64% with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth from $3.8B in 2022 to $5.14B in 2025, maintaining net margins above 21%. Recent earnings show mixed results with a Q3 2025 beat but Q1 2026 miss, while the company continues infrastructure investments and community initiatives.
AWK presents a stable utility investment with moderate upside to the $137 consensus target. Key risks include regulatory approvals for rate increases and high capital expenditures. Analyst sentiment is balanced with 47% buy ratings, though recent earnings misses warrant caution ahead of Q2 2026 results on July 29, 2026.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →